Avoiding Ghostwriting in Pharma-Funded Studies

Pharma- and device-funded clinical studies carry two authorship risks that occur together more often than most sponsors and investigators realize: ghost authorship, where a professional medical writer or company employee drafts the manuscript but is left off the byline and out of the acknowledgments, and honorary (gift) authorship, where a senior clinician or sponsor employee is added to the byline despite not meeting authorship criteria. Both distort the scientific record about who actually did the work, and both are specifically named as misconduct risks in ICMJE‘s authorship guidance and in industry’s own Good Publication Practice (GPP 2022) standard. This guide sets out the practical safeguards that keep an industry-sponsored authorship process defensible, from full contributor disclosure through to a signed GPP 2022-compliant acknowledgment of writing assistance.

This page assumes you already know what ghost and honorary authorship are; for the definitions themselves, see the Ghost authorship and Gift authorship dictionary entries, and the comparison of Ghost Authorship vs. Gift Authorship. What follows is specific to the industry-sponsored setting, where a commercial funder, a contract research organization, and one or more professional medical writers sit alongside the academic investigators, and where the incentives that produce both problems are structurally built into the study rather than incidental to it.

Why industry sponsorship raises the stakes

In an investigator-led academic study, ghost and honorary authorship usually arise from informal habit: a lab head is added out of courtesy, a statistician’s writing contribution goes unmentioned. In an industry-sponsored study, the same failures can arise from a structured process that was never designed with authorship integrity as a constraint. A sponsor’s medical affairs or publications team routinely commissions a professional medical writer, sometimes employed by the sponsor and sometimes by a specialist medical communications agency, to prepare the first draft from the clinical study report. Named academic authors, often key opinion leaders identified during trial recruitment, are then invited to review, revise, and sign off. Handled transparently and with genuine investigator control over content, this is standard, permitted practice under GPP 2022 and ICMJE. Handled opaquely, it produces exactly the ghost-authorship pattern regulators, journals, and COPE have flagged for over two decades: a substantial, undisclosed drafting contributor, and named authors whose actual intellectual input may fall short of the ICMJE criteria they are nonetheless being asked to attest to.

The honorary-authorship risk runs in parallel. Sponsors have a commercial interest in a paper carrying credible, senior clinical names; investigators and institutions have an interest in accumulating publications and in maintaining the sponsor relationship for future trials. Both pressures point toward adding names that lend credibility or preserve goodwill rather than names that reflect the four ICMJE authorship criteria. Because the underlying incentive (commercial credibility, career currency, and the writing capacity is centralized in the sponsor rather than distributed across an academic co-author group), the same publication can carry both a ghost author and an honorary author at once: the writer who did the drafting is invisible, and a well-known clinician who did comparatively little sits in the byline instead.

Safeguard 1: Establish an authorship and publication plan before the manuscript is drafted

The single most effective safeguard is procedural and happens before a single word is drafted. GPP 2022 recommends that sponsors and investigators agree a publication plan, including who will be an author, what each person’s expected contribution is, and how professional writing support will be used and disclosed, at or near study initiation, not after topline results are available and a manuscript timeline is already under commercial pressure. Where a publication or steering committee governs a multi-site industry-sponsored trial, authorship criteria and the role of any medical writer should be written into that committee’s charter alongside its scientific responsibilities.

Deciding authorship after the data are in and the manuscript is drafted is where honorary-authorship pressure is strongest, because by that point the byline decision is entangled with relationship management rather than governed by a documented process agreed in advance.

Safeguard 2: Apply the ICMJE criteria to every proposed name, including the sponsor’s own staff

Every person proposed for the byline, whether an academic investigator, a sponsor employee, or a CRO statistician, should be checked against all four ICMJE authorship criteria: substantial contribution to conception/design or data acquisition/analysis; drafting or critically revising the work for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work. All four must be met; meeting only one or two, however senior the person or however useful their name would be to the study’s visibility, is gift authorship by ICMJE’s own definition. The same test applies to sponsor personnel: a medical director or biostatistician employed by the sponsor who meets all four criteria is legitimately a co-author and should be named as such, with their affiliation and role disclosed exactly as any academic co-author’s would be. The test is contribution, not employer.

In practice this means checking the criteria against each name at least twice: once when the publication plan is set, and again just before submission, since a person’s actual contribution can diverge from what was anticipated at planning stage.

Safeguard 3: Disclose every non-author contribution, especially medical writing support

Anyone who contributed substantively but does not meet all four ICMJE criteria, most commonly a professional medical writer, a statistician who ran but did not design the analysis, or a sponsor employee who provided data access or technical review, belongs in a named acknowledgments section, not on the byline and not omitted entirely. GPP 2022 is explicit that professional writing or editorial assistance must be disclosed by name (or, where a policy permits, by role and affiliation) together with the funding source that paid for it. The acceptable industry norm is a short, standard disclosure of the kind ICMJE and GPP 2022 both endorse: naming the writer, their affiliation or employer, and the fact that the work was funded by the study sponsor. What is not acceptable, and what constitutes ghost authorship, is a manuscript that discloses no writing assistance at all despite a professional writer having produced the first draft.

This disclosure obligation extends to non-writing sponsor contributions too: statistical programming, data monitoring committee input, and study design input from sponsor employees who do not meet full authorship criteria should be named in the acknowledgments or methods section, following the same logic that governs any non-author contributor, covered in more general terms for the acknowledgments obligation broadly.

Safeguard 4: Put the disclosure and authorship attestation in writing, per journal, before submission

Most biomedical journals now operationalize ICMJE’s recommendations through a mandatory authorship contribution form and a conflict-of-interest disclosure form that every listed author must complete individually, not as a single group sign-off from the sponsor. For the mechanics of completing the conflict-of-interest side of this correctly, see ICMJE Conflict-of-Interest Disclosure Form: How to Complete It. Sponsors should not complete or pre-fill these forms on an author’s behalf; each named author attesting to meeting the ICMJE criteria, and to having reviewed and approved the final manuscript, is the mechanism that catches honorary authorship before submission, since an author who has not substantively engaged with the manuscript will struggle to complete the form accurately.

Safeguard 5: Preserve investigator control over content and interpretation

A publication written by a professional medical writer under sponsor direction is compatible with legitimate authorship only if the named academic authors retain genuine editorial control, meaning they can and do request substantive changes, including changes the sponsor may not prefer, and their approval of the final version is real rather than a formality. Publication agreements between sponsors and investigator sites should state this explicitly: that the sponsor may propose but not dictate content, that authors have the right to publish negative or unfavorable results, and that final approval rests with the named authors, not with sponsor sign-off. Where this control is absent, whatever the byline says, the paper functions editorially as sponsor-authored work with borrowed academic names, which is the substance, not just the appearance, of the ghost/honorary authorship problem.

Safeguard 6: Route disputes and after-the-fact discoveries through a documented process

Ghost- or honorary-authorship concerns sometimes surface after submission or even after publication, when a co-author, reviewer, or reader raises a question about who actually wrote or contributed to the paper. These should be handled the same way any authorship dispute is: through the journal’s and institution’s documented process rather than informal negotiation between sponsor and academic author, using COPE’s published guidance as the reference framework. See COPE’s Flowchart for Suspected Ghost, Guest, or Gift Authorship and, for broader authorship conflicts, Resolving Authorship Order Disputes. Institutions with a research integrity office should route sponsor-related authorship concerns there rather than leaving resolution solely to the sponsor’s publications team, given the inherent conflict of interest in the sponsor investigating a dispute about its own commissioned manuscript.

Who is responsible for what

Sponsor / medical affairs or publications team: fund and disclose medical writing support by name; do not draft or approve the author list unilaterally; build authorship planning into the publication plan at study start; do not pre-complete author disclosure forms.
Named academic authors (including the corresponding author): verify their own contribution meets all four ICMJE criteria before accepting a byline placement; exercise real editorial control over the draft; complete their own conflict-of-interest and contribution forms individually.
Professional medical writer: be named in the acknowledgments (or, where their contribution independently meets the ICMJE criteria, as a co-author) together with their funding source and affiliation; maintain a documented contribution trail (draft versions, correspondence) that supports the disclosure statement if questioned.
Institution / research integrity office: provide investigators with authorship-criteria guidance independent of the sponsor relationship, and serve as the venue for resolving disputes rather than leaving resolution to the commercial party.

Frequently asked questions

Is it ever acceptable for a sponsor employee to be a named author?

Yes, provided that employee meets all four ICMJE authorship criteria in the same way any other proposed author would have to. Employment by the sponsor is not disqualifying and does not by itself make someone an honorary author; the disqualifying factor is not meeting the criteria, regardless of who employs the person.

Does disclosing a medical writer’s involvement fully solve the ghost-authorship problem?

Disclosure is necessary but not sufficient on its own. GPP 2022 and ICMJE both expect disclosure of writing assistance together with genuine investigator control over the manuscript’s content; a fully disclosed writer working under a process where named authors have no real ability to change the draft still raises editorial-independence concerns, even though it no longer meets the technical definition of ghost authorship.

What is the difference between this and general acknowledgments guidance?

The acknowledgments mechanism for crediting non-author contributors, such as medical writers and statisticians, is the same everywhere; what is specific to the industry-sponsored setting is the combination of commercial incentive, centralized writing capacity, and the structured publication-planning process that sponsors typically run, all of which raise the stakes and change where the practical safeguards need to sit in the workflow.

Where should a dispute about a sponsor-commissioned manuscript’s authorship be raised first?

With the journal, following its stated authorship-dispute process, and in parallel with the relevant institution’s research integrity office if an academic author is involved; COPE’s flowchart guidance is the standard reference both parties are likely to be following.

Industry-Sponsored Research Authorship: Avoiding Ghostwriting and Honorary Authorship